Women remain underrepresented in clinical trials for cardiovascular diseases
An international team has analysed gender representation in more than 1,000 clinical trials on cardiovascular disease between 2017 and 2023, involving more than one million people. Although female participation has increased, especially in areas such as obesity and heart failure, women continue to be underrepresented overall compared to men. The results, presented at the European Society of Cardiology (ESC) Congress held in Madrid from 29 August to 1 September, are published in JAMA Network Open.